Why Novo Nordisk May Offer Better Value Than Eli Lilly

The pharmaceutical sector is currently dominated by the high-stakes rivalry between Eli Lilly and Novo Nordisk, particularly within the lucrative GLP-1 weight-loss drug market. While Eli Lilly has captured significant market share and investor enthusiasm with the rapid growth of Mounjaro and Zepbound, a contrarian perspective suggests that Novo Nordisk may currently represent a more compelling opportunity for value-oriented and dividend-focused investors.

Eli Lilly’s recent performance has been undeniably robust, with triple-digit growth in its key obesity franchises. Conversely, Novo Nordisk has faced operational challenges, including supply constraints and increased competition, leading to a more modest growth trajectory. However, Novo Nordisk remains a formidable competitor, recently introducing an oral version of Wegovy that could capture a significant segment of the market that prefers non-injectable treatments. This indicates that the race for dominance in the GLP-1 space is far from over.

From a financial standpoint, the divergence between the two companies is stark. Eli Lilly trades at a premium valuation, reflecting its current market leadership, but offers a relatively low dividend yield. In contrast, Novo Nordisk is trading at a significantly lower price-to-earnings ratio and provides a robust dividend yield of approximately 4%. With a sustainable payout ratio, Novo Nordisk offers a more attractive entry point for those seeking income and value.

Ultimately, while 2026 may be a challenging year for Novo Nordisk due to pricing pressures, the company’s current market valuation appears to have priced in these headwinds. For investors looking beyond the immediate hype surrounding Eli Lilly, Novo Nordisk presents a strategic opportunity to gain exposure to the weight-loss drug market at a more reasonable price, backed by a reliable dividend stream.